Loading…
← CockpitCompetitor Analysis › 300138.SZ Chenguang Biotech Group Co., Ltd. Class AOpen in the cockpit ↗

Chenguang Biotech Group Co., Ltd. Class A300138.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Food: Specialty/Candy
Momentum leader 95
Mkt cap
$896M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$13.7M
20-day average traded
Fwd P/E
15.4×
forward earnings
ROIC−WACC
+3.7 pp
WACC 5.0%
Hurdle
-13 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · CNYCN¥12.17
1D-2.6%
1W-2.2%
1M+4.0%
3M+8.7%
6M+9.2%
YTD-1.9%
1Y-7.0%
ATR %3.5%
52w lowhigh23.0% off high

What Chenguang Biotech does

Employees: 2,079

Chenguang Biotech at a glance

Size Chenguang Biotech (300138.SZ) is a China Consumer Staples company (Food: Specialty/Candy) with a market value of $896M, the 2368th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.17 on 18 Nov 2026.

Performance Over six months the shares gained 9.2%, against -6.8% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue fell 3.9% over the last twelve months (peer median +5.0%); the operating margin is 6.2% (peer median 6.2%).

Valuation It trades at 15.4× forward earnings against a peer median of 18.5× (5th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026300138.SZ 111Peer median 92
Six months, rebased to 100: Chenguang Biotech against the median of its 20 peers (local-currency closes).

Chenguang Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.54BCN¥6.55BCN¥6.98BCN¥6.87BCN¥6.29B
Revenue growth—-6%+2%+9%—
Gross profitCN¥897MCN¥811MCN¥488MCN¥754MCN¥827M
EBITDAn/aCN¥595MCN¥287MCN¥633MCN¥593M
Net incomeCN¥335MCN¥369MCN¥94.0MCN¥480MCN¥434M
Free cash flowCN¥131MCN¥147M-CN¥334M-CN¥700MCN¥579M
Capital expenditureCN¥154MCN¥135MCN¥150MCN¥189MCN¥176M
Total debtCN¥4.43BCN¥5.12BCN¥4.91BCN¥4.22BCN¥2.84B

Quarterly statements and history in the cockpit →

Chenguang Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-40%-20%0%+20%002956495828036000731060360914750026504914WEST605338F030018006053396001272815002481600866300138.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Chenguang Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×002956495828036000731060360914754914ORKLAINDIA003000F03600866300138.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chenguang Biotech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%0%25%50%0029562803606036091475002650WESTORKLAINDIA605338F030018002815002481300138.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chenguang Biotech is the large dot.

Chenguang Biotech competitors and peer comparison

How Chenguang Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chenguang Biotech against its 20 peers (data as of 18 Nov 2026)
Measure300138.SZPeer medianRank in peer set
1-month return+4.0%-1.0%4th highest of 21
6-month return+9.2%-6.8%4th highest of 20
Distance from 52-week high-23.0%-26.1%9th highest of 21
Revenue growth (TTM)-3.9%+5.0%4th lowest of 21
Operating margin6.2%6.2%11th highest of 21
Forward P/E15.4×18.5×5th cheapest of 14
Growth the price implies (Req g, 7 yrs)-1.6%1.0%7th least demanding of 13
Growth delivered (Del g)+10.9%+8.4%6th highest of 13
Hurdle (Req g minus delivered)-12.5 pp-10.5 pp6th least demanding of 13
ROIC minus cost of capital+3.7 pp-0.7 pp8th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Chenguang Biotech 300138.SZChina$896M+9%-4%6%15.4×-1.6%+10.9%
Guilin Seamild Foods 002956.SZChina$900M-11%+21%11%22.1×8.2%+17.0%
T. Hasegawa 4958.TJapan$900M+14%+8%12%18.5×n/an/a
Lotte Wellfood 280360.KSSouth Korea$921M+15%+5%4%10.1×-1.8%+15.2%
Otoki 007310.KSSouth Korea$846M-18%+3%4%8.9×n/an/a
Wellhope Foods 603609.SSChina$841M-5%+7%0%52.0×53.7%+8.5%
Nissin Foods 1475.HKHong Kong$833M-14%+5%12%19.0×-13.7%+2.6%
Jiajia Food 002650.SZChina$981M-27%-9%-10%n/a3.8%-10.0%
Takasago International 4914.TJapan$817M+9%+4%3%13.6×n/an/a
Westrock Coffee WESTUnited States$817M-4%+16%1%n/a45.8%+11.1%
Orkla India ORKLAINDIA.NSIndia$814M-11%+6%14%21.7×13.1%+5.3%
Zhongyin Babi Food 605338.SSChina$814M-5%+2%17%18.8×-3.1%+13.8%
Jinzai Food 003000.SZChina$812M-15%+14%8%17.7×n/an/a
Food Empire F03.SISingapore$811M-34%+14%16%10.8×-11.8%+14.9%
Jiangxi Qiyunshan Food 2797.HKHong Kong$1.00Bn/a-7%17%n/an/an/a
ORION 001800.KSSouth Korea$1.02B-7%+16%15%n/a-15.9%+8.3%
Namchow Food Group (Shanghai) 605339.SSChina$776M-27%-5%-1%n/an/an/a
JinJian Cereals Industry 600127.SSChina$772M+28%+1%-1%n/an/an/a
ARIAKE JAPAN 2815.TJapan$1.06B-4%+5%17%17.6×-6.1%+6.1%
Yan Tai Shuang Ta Food 002481.SZChina$750M-5%+5%2%n/a16.6%+1.2%
Star Lake Bioscience 600866.SSChina$1.07B-24%-3%0%37.4×n/an/a

Questions

Which companies are Chenguang Biotech's closest peers?
The cockpit's peer set: Guilin Seamild Foods (002956.SZ), T. Hasegawa (4958.T), Lotte Wellfood (280360.KS), Otoki (007310.KS), Wellhope Foods (603609.SS), Nissin Foods (1475.HK), Jiajia Food (002650.SZ), Takasago International (4914.T).
Is Chenguang Biotech expensive compared with its peers?
On forward p/e it trades at 15.4× against a peer median of 18.5×, 5th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Chenguang Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned +9.2% against -6.8% for the median peer; over one year -7.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.